mecamylamine has been researched along with Parkinsonian Disorders in 2 studies
Mecamylamine: A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stuckenholz, V | 1 |
| Bacher, M | 1 |
| Balzer-Geldsetzer, M | 1 |
| Alvarez-Fischer, D | 1 |
| Oertel, WH | 1 |
| Dodel, RC | 1 |
| Noelker, C | 1 |
| Yanagida, T | 1 |
| Takeuchi, H | 1 |
| Kitamura, Y | 1 |
| Takata, K | 1 |
| Minamino, H | 1 |
| Shibaike, T | 1 |
| Tsushima, J | 1 |
| Kishimoto, K | 1 |
| Yasui, H | 1 |
| Taniguchi, T | 1 |
| Shimohama, S | 1 |
2 other studies available for mecamylamine and Parkinsonian Disorders
| Article | Year |
|---|---|
The α7 nAChR agonist PNU-282987 reduces inflammation and MPTP-induced nigral dopaminergic cell loss in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benzamides; Bridged Bicyclo Compounds; Calcium-Binding Prot | 2013 |
Synergistic effect of galantamine on nicotine-induced neuroprotection in hemiparkinsonian rat model.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Disease Models, Animal; Dopamine Uptake Inhibitors | 2008 |